| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/29/2005 | US20050215474 inducing a specific immune response to DNA vaccines; as an adjuvant, immunostimulants |
| 09/29/2005 | US20050215472 PSMA formulations and uses thereof |
| 09/29/2005 | US20050214937 Surface proteins of leptospira |
| 09/29/2005 | US20050214910 Chordin-like molecules and uses thereof |
| 09/29/2005 | US20050214869 Molecular interactions in hematopoietic cells |
| 09/29/2005 | US20050214856 Nucleotide sequences coding bone morphogenic protein for identifying modulators for treatment of bone diseases |
| 09/29/2005 | US20050214790 Nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatment of schizophrenia |
| 09/29/2005 | US20050214781 Ovarian specific nucleic acid (OSNA) for use in diagnosis, prevention and treatment of cell proliferative disorders; immunotherapy; genetic vaccines |
| 09/29/2005 | US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders |
| 09/29/2005 | US20050214378 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 09/29/2005 | US20050214359 Co-micelles; membrane proteins; for intranasal delivery; influenza hemagglutinin protein; neuramimidases |
| 09/29/2005 | US20050214355 Sterically stabilized cationic liposomes (SSCL) encapsulating K type oligodeoxynucleotide (ODN) including CpG motif; interleukins; fusion proteins; immunology; antitumor agents |
| 09/29/2005 | US20050214329 Vaccine |
| 09/29/2005 | US20050214328 Administering an immunomodulatory compound (1-oxo- or 1,3-dioxo-2-(2,6-dioxopiperidin-3yl) isoindolines); inhibiting cell growth or proliferation, removing or improving acne scar, or reducing or correcting wrinkle line; senile keratosis |
| 09/29/2005 | US20050214325 Administering a neurotoxin and a neuron growth inhibitor to treat or prevent dermatological, urological, thyroid, optical, and neurological conditions; dystonia, hyperthyroidism, hypothyroidism, Graves' disease, goiter, thyroiditis, cancer, migraine, chronic pain, fibromyalgia, stroke, brain injury |
| 09/29/2005 | US20050214324 Culturing avian cells permissive for productive replication of the virus in a serum free medium containing a growth factor or an attachment factor, infecting of the cells with the virus, and cultivating in serum free media until progeny virus is produced |
| 09/29/2005 | US20050214323 Modified vaccinia ankara virus variant and cultivation method |
| 09/29/2005 | US20050214322 Vaccines containing a saponin and a sterol |
| 09/29/2005 | US20050214320 Mycobacterium vaccae; enhancement of immune Th1 or Th2 responses to heterologous antigens; tuberculosis, autoimmune thyroiditis, insulin-dependent diabetes mellitus, multiple sclerosis, Crohn's disease, peptic ulcers, organ transplant rejection, sarcoidosis, asthma, allergic rhinitis, cancer, lupus |
| 09/29/2005 | US20050214318 Immunogenic composition and method of developing a vaccine based on fusion protein |
| 09/29/2005 | US20050214317 A binding site of the cystosolic protein cyclophilin A on human immunodeficiency virus capsid protein, which may be expressed by a recombinant viral, bacterial or yeast carrier; may be treated with neuraminidase or trypsin to remove sialic acid; immune stimulant such as teichoic acid or zymosan |
| 09/29/2005 | US20050214316 Generating and sequencing an infectious bursal disease virus cDNA from sample suspected of having a strain of IBDV, aligning the sequence with one or more IBDV sequences, and comparing relatedness of aligned IBDV sequences; selecting a vaccine for chickens, ducks, geese, pheasants, quail and turkeys. |
| 09/29/2005 | US20050214315 Antibodies to human IL-17F and other CTLA-8-related proteins and methods related thereto |
| 09/29/2005 | US20050214313 Extracellular domain of CTLA4, with (a) an alanine at position +29 substituted with tyrosine, leucine, tryptophan, or threonine, and (b) a leucine at position +104 substituted with glutamic acid; binds CD80 and/or CD86 with greater avidity; inhibiting graft versus host disease |
| 09/29/2005 | US20050214312 Heat shock protein-based vaccines and immunotherapies |
| 09/29/2005 | US20050214311 Immunocomplex of an antigen, especially a tumor-associated antigen, bacterial or viral antigen, and Fas ligand as an adjuvant; fusion protein; nucleic acid; treating cancer |
| 09/29/2005 | US20050214310 Drug delivery of an antibody-enzyme conjugate of an antibody (monoclonal antibody L49) reactive with an antigen on the surface of tumor cells conjugated to an enzyme ( beta-lactamase) that converts a nitrogen mustard-type prodrug into the more cytotoxic parent drug |
| 09/29/2005 | US20050214308 by administering a STIgMA polypeptide or its agonist; autoimmune, respiratory, kidney, skin, cardiovascular disorders, hepatitis |
| 09/29/2005 | US20050214307 Antibody conjugates for treatment of neoplastic disease |
| 09/29/2005 | US20050214306 Surface proteins of leptospira |
| 09/29/2005 | US20050214305 VEGI, an inhibitor of angiogenesis and tumor growth |
| 09/29/2005 | US20050214303 Methods for damaging cells using effector functions of anti FAM3D antibodies |
| 09/29/2005 | US20050214302 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis |
| 09/29/2005 | US20050214301 Antibodies specific for BCR-ABL fusion protein and uses thereof |
| 09/29/2005 | US20050214300 Methods for treating cancer using Porimin as a target |
| 09/29/2005 | US20050214299 Method of inhibiting stenosis and restenosis |
| 09/29/2005 | US20050214297 Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts |
| 09/29/2005 | US20050214296 Methods of modulating cytokine activity; related reagents |
| 09/29/2005 | US20050214295 Combined chemotherapy compositions and methods for the treatment of cancer, ischemia-reperfusion injury, and septic shock |
| 09/29/2005 | US20050214294 Diabetic nephropathy therapies |
| 09/29/2005 | US20050214293 Containing heavy and light chain complementarity determining region 1,2 and 3 components of amino acid sequences 1-6; reduced immunogenicity; increased affinity and avidity; improved cell culturing |
| 09/29/2005 | US20050214292 Monitoring and inhibiting midkine gene expression activity; lupus nephritis; kits |
| 09/29/2005 | US20050214291 Treatment method |
| 09/29/2005 | US20050214290 Methods of blocking tissue destruction by autoreactive T cells |
| 09/29/2005 | US20050214289 Antibodies against Nogo receptor |
| 09/29/2005 | US20050214288 Antibodies against Nogo receptor |
| 09/29/2005 | US20050214287 Methods and compositions for modulating angiogenesis |
| 09/29/2005 | US20050214286 Polymer-bound antibody cancer therapeutic agent |
| 09/29/2005 | US20050214285 Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses |
| 09/29/2005 | US20050214284 Soluble TCR molecules and methods of use |
| 09/29/2005 | US20050214283 Antibodies to CD44 glycoforms and uses thereof |
| 09/29/2005 | US20050214282 Expressed genes that define the osteoclast phenotype |
| 09/29/2005 | US20050214281 G-protein coupled receptor |
| 09/29/2005 | US20050214280 Utilizing antibody, antisense agent, RNA interference component and/or triplex nucleic acid forming molecule as vascular endothelial growth factor B antagonist |
| 09/29/2005 | US20050214279 Synergistic combination of complement protein and one or more binding antibodies; kits; bioassay technique |
| 09/29/2005 | US20050214278 Antibody-containing solution pharmaceuticals |
| 09/29/2005 | US20050214268 Methods for treating tumors and cancerous tissues |
| 09/29/2005 | US20050214266 Pretreating hematopoietic stem cells harvested from blood or bone marrow, tissue materials and/or organs prior to surgical implantation; preventing infections |
| 09/29/2005 | US20050214265 Tolerance conditioning and multiday delayed transplantation; depleting alpha beta - and gamma delta -TCR+ T cells and/or CD8+ T cells |
| 09/29/2005 | US20050214256 Expression cassette generated from these sequences; generating an immune response in a subject |
| 09/29/2005 | US20050214252 Chordin-like molecules and uses thereof |
| 09/29/2005 | US20050214211 Active and/or passive immunization; accurate early stage, localized tumor detection |
| 09/29/2005 | US20050214210 Antibodies that immunospecifically bind to TRAIL receptors |
| 09/29/2005 | US20050214209 Anitcancer and antiproliferative agents; tumor necrosis factor related apoptosis inducing ligand (TRAIL); combination of amino acid sequences from VHCDR1, 2 or 3 with VLCDR1, 2 or 3 of sequence numbers 42 through 53; isolated cells; kits |
| 09/29/2005 | US20050214208 Anitcancer and antiproliferative agents; tumor necrosis factor related apoptosis inducing ligand (TRAIL); combination of amino acid sequences from VHCDR1, 2 or 3 with VLCDR1, 2 or 3 of sequence numbers 42 through 56; isolated cells; kits |
| 09/29/2005 | US20050214207 Antibodies that immunospecifically bind toTRAIL receptors |
| 09/29/2005 | US20050214206 Antibodies that immunospecifically bind to TRAIL receptors |
| 09/29/2005 | US20050214205 Antibodies that immunospecifically bind to TRAIL receptors |
| 09/29/2005 | DE102004011564A1 Impfstoff zur Vorbeugung und/oder Behandlung einer Herpes-Virus Infektion A vaccine for the prevention and / or treatment of a herpes viral infection |
| 09/29/2005 | CA2598879A1 Prostate stem cell |
| 09/29/2005 | CA2560953A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient |
| 09/29/2005 | CA2560532A1 Method of vaccination against testicular bvdv infection |
| 09/29/2005 | CA2560305A1 Human anti-epidermal growth factor receptor antibody |
| 09/29/2005 | CA2560261A1 Method for the delivery of sustained release agents |
| 09/29/2005 | CA2560224A1 Analysis of saccharide vaccines without interference |
| 09/29/2005 | CA2560185A1 Novel assay for the separation and quantification of hemagglutinin antigens |
| 09/29/2005 | CA2559996A1 Combination vaccines with low dose of hib conjugate |
| 09/29/2005 | CA2559969A1 Streptococcus agalactiae vaccine |
| 09/29/2005 | CA2559840A1 Prostatic acid phosphatase antigens |
| 09/29/2005 | CA2559272A1 Novel peanut skin extract as a vaccine adjuvant |
| 09/29/2005 | CA2559235A1 Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof and therapeutic uses thereof |
| 09/29/2005 | CA2559211A1 Detection, isolation and uses of renalase (monoamine oxidase c) |
| 09/29/2005 | CA2558730A1 Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances |
| 09/29/2005 | CA2558371A1 Methods of modulating immune responses by modulating tim-1 and tim-4 function |
| 09/29/2005 | CA2558096A1 Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition |
| 09/29/2005 | CA2557844A1 Infectious bursal disease virus antigenic isolates and vaccines |
| 09/29/2005 | CA2557443A1 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide |
| 09/29/2005 | CA2556080A1 Novel tat complexes, and vaccines comprising them |
| 09/29/2005 | CA2556032A1 Site-specific chemical modification of hiv gp41-derived peptides |
| 09/29/2005 | CA2554018A1 Lyophilization method to improve excipient crystallization |
| 09/29/2005 | CA2552508A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 09/28/2005 | EP1580266A1 Screening method |
| 09/28/2005 | EP1580195A1 Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy |
| 09/28/2005 | EP1579871A1 Vascular endothelial cell growth factor antagonists and uses thereof |
| 09/28/2005 | EP1579870A1 Vaccine comprising polynucleotide |
| 09/28/2005 | EP1579863A2 Combination therapy with anti-gastrin G17 antibodies for the treatment of tumors |
| 09/28/2005 | EP1579214A2 Methods of screening for anti-inflammatory drugs and use thereof |
| 09/28/2005 | EP1579213A1 Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin beta c. |
| 09/28/2005 | EP1578991A2 Methods of diagnosing & treating diabetes and insulin resistance |
| 09/28/2005 | EP1578959A1 Immunizing fish against viral infection |